Background Because of the absence of recognized, well-proven effective therapies, the coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be a serious global concern. As a result, most countries have been affected, resulting in tremendous stress on healthcare systems (1, 2).

The clinical description of COVID-19 has ranged from asymptomatic or mild to excessively severe pneumonia, mostly causing adult respiratory distress syndrome (ARDS), which is a condition that needs extended mechanical breathing or extracorporeal membrane oxygenation (ECMO) (3,4).

In the pathophysiology of severe COVID-19 disease, the patients’ immune response has a fundamental role. It has been observed that the immune response becomes dysregulated in various patients. Evidently, COVID-19 pneumonia is accompanied by increased inflammation and immunosuppression (5). The significant symbol of pulmonary pathology in COVID-19 patients is diffuse alveolar destruction, which is frequently related to the thickening of the alveolar walls with infiltration caused by the inflammatory cells, mainly by macrophages and mononuclear cells (6). It has also been remarked that COVID-19 patients develop...
significant pulmonary vascular endothelial cell injury and endothelialitis, connected with intravascular thrombosis and microangiopathy (7,8). COVID-19 disease is mainly correlated with numerous raised inflammatory biomarkers, cytokines, and chemokines, which tend to appear very high in severe cases.

Although many proposed therapies for reducing the inflammatory response are being assessed, there is still a lack of robust, tangible proof of benefit. Corticosteroids have shown positive, beneficial outcomes in overcoming hyper inflammation and ARDS (3, 9-11). Furthermore, they can help as a convenient and affordable treatment choice.

However, corticosteroid use has some well-known adverse effects, like delayed viral clearance, opportunistic infections, and suppressed hypothalamic-pituitary-adrenal axis (12-14). Previous studies performed during Middle East respiratory syndrome (MERS)-CoV and SARS-CoV exhibited delayed viral clearance, opportunistic infections, and hyperglycemia (15-17). Consequently, the positive impact of corticosteroids on COVID-19 patients has been observed in observational studies and randomized controlled trials (RCTs). The RECOVERY trial, one of the first large randomized trials, reported that dexamethasone resulted in decreased 28-day all-cause death rate in a prospective meta-analysis of seven RCTs (19).

While the World Health Organization (WHO) initially had advised in contradiction of the corticosteroid therapy, as of September 2, 2020, and after the meta-analysis done by the WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) working group, it now recommends systemic corticosteroids rather than no systemic corticosteroids in order to manage severe and critical COVID-19 cases who required supplemental oxygen therapy or mechanical ventilation (18). Additionally, corticosteroids were linked to a lower 28-day all-cause death rate in a prospective meta-analysis of seven RCTs (19).

Materials and Methods

Participants

We conducted a retrospective study consisting of COVID-19 patients aged ≥20 years admitted to all departments, including intensive care unit (ICU) in Hormozgan province. COVID-19 infection was confirmed by real-time reverse transcriptase polymerase chain reaction (PCR) (RT-PCR) assay nasopharyngeal swab specimens between February 2020 and October 2020. RT-PCR tests had been performed on specimens from nasopharyngeal swabs using the STANDARD M nCoV Real-Time Detection Kit (SD Biosensor Inc., South Korea). The kit is based on TaqMan probe technology targeting RdRp and E genes. Pregnant women and patients lacking most of the required information were excluded.

Study Design

The patients’ data were extracted from the electronic medical records using standardized data collection sheet. We recorded information on age, gender, pre-existing medical conditions, including hypertension, diabetes mellitus (DM), ischemic heart disease (IHD), chronic lung disease (CLD), chronic kidney disease (CKD), malignancy, oxygen saturation, and cigarette smoking.

Statistical Analysis

SPSS software (version 20.0) was used for data analysis. Mean, standard deviation, frequency, and percentages were used to describe the results. Independent t test and chi-square test were applied to compare quantitative and qualitative variables, respectively, among the dead and survivor groups. The binary logistic regression model was used to determine the independent role of corticosteroid use and other variables in mortality. A P value less than 0.05 was considered as significant level.

Results

Among 1610 confirmed COVID-19 cases, 150 (9.3%) died. Table 1 compares demographics, clinical conditions, and corticosteroid use between the dead and survivor groups. According to Table 1, 58.5% of the hospitalized patients and 58.7% of dead patients were male. Although the male gender had a higher proportion of mortality than females, this difference was not significant. The mean age was markedly higher in the dead group than the survivor group. The mortality rate in subjects older than 60 years was 18.8% and 1.5% among people aged 20-40 years, which was statistically significant (P<0.001). The patients who received corticosteroids had a significantly higher mortality rate than patients not taking corticosteroids (12.7% vs. 7.0%) (P<0.001). Likewise, the most significant mortality rate was related to cerebrovascular disease (CVD) (33.3%), followed by IHD (25.2%), cancer (22.7%), hypertension (17.9%), and
A low oxygen saturation (< 93%) increased the fatality rate by about four times compared to normal oxygen saturation (\( P < 0.001 \)).

Table 2 provides information about crude and adjusted odds ratio (aOR) of different variables, including corticosteroid taking, regarding the mortality rate. Logistic regression analysis showed that age was the most significant risk factor of mortality. The OR of fatality rate in patients older than 60 years was nearly 10 times higher than people aged less than 40 years (aOR: 9.79, 95% CI: 4.41-21.74). The second influential factor in mortality was a low oxygen saturation (< 93%), so that it raised mortality rate by more than 3.5 times compared to oxygen saturation ≥ 93% (aOR: 3.67, 95% CI: 2.54-5.31). Another remarkable factor was the IHD (aOR: 2.85, 95% CI: 1.88-4.31). Also, using corticosteroids increased the chance of

| Variables                              | Death         | Adjusted Death |
|----------------------------------------|---------------|----------------|
| Age categories                         |               |                |
| 20-40                                  | 1.0           | 1.0            |
| 41-60                                  | 4.46 (1.97-10.07) | <0.001        |
| > 60                                   | 15.65 (7.19-34.07) | <0.001        |
| Gender                                 |               |                |
| Female                                 | 1.0           | 1.0            |
| Male                                   | 1.18 (0.84-1.67) | -             |
| Corticosteroid taking                  |               |                |
| No                                     | 1.0           | 1.0            |
| Yes                                    | 1.93 (1.38-2.71) | 0.023         |
| Diabetes mellitus                      |               |                |
| No                                     | 1.0           | 1.0            |
| Yes                                    | 2.01 (1.38-2.92) | -             |
| Hypertension                           |               |                |
| No                                     | 1.0           | 1.0            |
| Yes                                    | 2.81 (1.97-4.01) | -             |
| Ischemic heart disease                 |               |                |
| No                                     | 1.0           | 1.0            |
| Yes                                    | 4.46 (3.06-6.51) | <0.001        |
| Cerebrovascular disease                |               |                |
| No                                     | 1.0           | 1.0            |
| Yes                                    | 5.02 (1.85-13.59) | 0.053         |
| Asthma                                 |               |                |
| No                                     | 1.0           | 1.0            |
| Yes                                    | 1.19 (0.46-3.06) | -             |
| Chronic lung disease                   |               |                |
| No                                     | 1.0           | 1.0            |
| Yes                                    | 2.10 (0.73-6.57) | -             |
| Chronic kidney disease                 |               |                |
| No                                     | 1.0           | 1.0            |
| Yes                                    | 2.14 (1.14-3.99) | -             |
| Cancer                                 |               |                |
| No                                     | 1.0           | 1.0            |
| Yes                                    | 2.92 (1.06-8.05) | -             |
| O2 saturation ≤ 93%                    |               |                |
| No                                     | 1.0           | 1.0            |
| Yes                                    | 4.54 (3.21-6.43) | <0.001        |
| Cigarette smoking                      |               |                |
| No                                     | 1.0           | 1.0            |
| Yes                                    | 2.29 (0.93-5.67) | -             |

Reference was survivors.
mortality by 50% (aOR: 1.53, 95% CI: 1.06-2.22).

**Discussion**

In this study, we investigated the effect of systemic corticosteroids on mortality rates in 1610 COVID-19 patients in the hospitals of Hormozgan province in Iran. Corticosteroids were utilized in 41.18% of the cases. The results showed that using corticosteroids was not beneficial in reducing the mortality rates of COVID-19 patients.

No effective antiviral therapy has been discovered since the outbreak of the new SARS-CoV-2 virus. As a result, COVID-19 patients are mostly treated with symptomatic therapy, mainly focusing on supportive care and oxygen therapy, based on previous SARS and MERS treatment experiences.

Since corticosteroids firstly were suggested as a treatment strategy for ARDS (22, 23), there has been a debate in the scientific community over whether COVID-19 patients should be adjunctively treated with them. The Guangzhou retrospective study on SARS suggested that corticosteroids could reduce mortality in critical patients (24). Likewise, a RCT found that early dexamethasone therapy could lower overall mortality in individuals with established moderate-to-severe ARDS (11).

At the beginning of the COVID-19 pandemic, physicians were advised to take caution in prescribing corticosteroids, as they may cause prolonged viral shedding and decreased viral clearance (25). However, prescribing corticosteroids became increasingly popular after a study conducted in Wuhan, China, revealed that using methylprednisolone decreased the risk of death among COVID-19 patients with ARDS and suggested that corticosteroids may be beneficial for patients who develop ARDS (26). Nevertheless, this study suffered some critical limitations, including that it was conducted at a single-center hospital with limited sample size, and the corticosteroid therapy was assessed in only a small sample size cohort of ARDS patients.

Studies have proposed that COVID-19 invasion prompts immunological and inflammatory responses, causing immune cells to release several pro- and anti-inflammatory cytokines, as well as significantly higher levels of inflammatory markers (27). The excessive release of cytokines leads to severe alveolar and airway damage, causing extensive destruction to the pulmonary vascular endothelial and alveolar epithelial cells, increased pulmonary vascular permeability, pulmonary edema, and hyaline membrane formation (28).

Pulmonary histological examinations from a COVID-19 patient revealed diffuse alveolar damage with cellular fibromyxoid exudates, hyaline membrane formation, and pulmonary edema, indicating ARDS. Furthermore, the biopsy samples from this study also revealed that the pathological hallmarks of COVID-19 greatly resemble those seen in MERS-CoV and SARS-CoV infections (29). These results suggest that COVID-19 infection is usually associated with increased immune and inflammatory responses, and immune factor concentrations are possibly linked with disease severity (30).

Corticosteroids are classic immunosuppressants that accomplish critical physiological processes, such as inhibiting the immunological response and in force as anti-inflammatory drugs to decrease systemic inflammation, all of which are critical in avoiding or delaying the development of pneumonias (31, 32).

Our finding showed that corticosteroid therapy was an independent factor for higher mortality rate. Although the Randomized Evaluation of COVID-19 therapy (RECOVERY) trial showed that treatment with corticosteroid was linked with lower mortality in severe and critical COVID-19 patients, we could not observe a similar association in our study (18). Moreover, the prospective meta-analysis by WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, consisting of seven randomized trials, revealed that patients who received corticosteroids had a lower mortality rate than those who did not receive corticosteroids, again contradicting our findings (19).

Our findings indicated that corticosteroid therapy had no favorable impact on the endpoint of death among COVID-19 patients, which is consistent with the results of a previous study conducted on MERS-CoV infection. In a multicenter study of 309 MERS patients, the crude mortality was higher in the group treated with corticosteroids, although later, the adjusted mortality showed no difference among the two groups (15). Moreover, the results from a multicenter RCT of patients with persistent ARDS did not support the routine use of corticosteroids. They even found an increased risk of mortality when treatment began late in the course of the disease (33).

This study had some limitations. The major limitation of the study is its retrospective aspect; further RCTs should be conducted to validate our results. Also, the findings are only applicable to centers with similar settings and COVID-19 admission volumes due to the single-center nature of the study. Therefore, meta-analyses using the findings of this study and other similar studies are required.

In conclusion, our study showed that the use of corticosteroids showed no evidence of benefit for decreasing the mortality rates among COVID-19 patients. So, we do not suggest using corticosteroids regularly for this purpose outside of a trial setting.

**Acknowledgments**

We would like to express our sincere gratitude to Professor Hossein Farshidi and Professor Teymouz Agha Mollaei for their supports.
This study is self-funded.

Funding/Support
This study is self-funded.

Funding/Support

References

1. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620-9. doi: 10.1172/jci137244.

2. Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393. doi: 10.1016/j.clim.2020.108393.

3. Villar J, Conflalonieri M, Pastores SM, Meduri GU. Rationale for prolonged corticosteroid treatment in the acute respiratory distress syndrome caused by coronavirus disease 2019. Crit Care Explor. 2020;2(4):e0111. doi: 10.1097/cce.0000000000000111.

4. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. doi: 10.1016/S0140-6736(20)30566-3.

5. Jamilouy H, Henry T, Belot A, Vel S, Fauter M, El Jammal T, et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 2020;19(7):102567. doi: 10.1016/j.autrev.2020.102567.

6. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A Review. JAMA. 2020;324(8):782-93. doi: 10.1001/jama.2020.12839.

7. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelitis, thrombosis, and angiogenesis in COVID-19. N Engl J Med. 2020;383(2):120-8. doi: 10.1056/NEJMoa2015432.

8. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endothelitis in COVID-19. Lancet. 2020;395(10234):1417-8. doi: 10.1016/S0140-6736(20)30937-5.

9. Alijotas-Reig J, Esteve-Valverde E, Belizna C, Selva-O’Callaghan A, Pardos-Gea J, Quintana A, et al. Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: a comprehensive review. Autoimmun Rev. 2020;19(7):102569. doi: 10.1016/j.autrev.2020.102569.
24. Chen RC, Tang XP, Tan SY, Liang BL, Wan ZY, Fang JQ, et al. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest. 2006;129(6):1441-52. doi: 10.1378/chest.129.6.1441.

25. Ling Y, Xu SB, Lin YX, Tian D, Zhu ZQ, Dai FH, et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chin Med J (Engl). 2020;133(9):1039-43. doi: 10.1097/cm9.0000000000000774.

26. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934-43. doi: 10.1001/jamainternmed.2020.0994.

27. Russell B, Moss C, George G, Santaolalla A, Cope A, Papa S, et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. ECancermedicalscience. 2020;14:1022. doi: 10.3332/ecancer.2020.1022.

28. Cruz-Topete D, Cidlowski JA. One hormone, two actions: anti- and pro-inflammatory effects of glucocorticoids. Neuroimmunomodulation. 2015;22(1-2):20-32. doi: 10.1159/000362724.

29. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420-2. doi: 10.1016/s2213-2600(20)30076-x.

30. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi: 10.1016/s0140-6736(20)30183-5.

31. Nasim S, Kumar S, Azim D, Ashraf Z, Azeem Q. Corticosteroid use for 2019-nCoV infection: a double-edged sword. Infect Control Hosp Epidemiol. 2020;41(10):1244-5. doi: 10.1017/ice.2020.165.

32. Yang Z, Liu J, Zhou Y, Zhao X, Zhao Q, Liu J. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J Infect. 2020;81(1):e13-e20. doi: 10.1016/j.jinf.2020.03.062.

33. Steinberg KP, Hudson LD, Goodman RB, Hough CL, Lanken PN, Hyzy R, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 2006;354(16):1671-84. doi: 10.1056/NEJMoa051693.